Trial
NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Multiple Myeloma
Intervention
AMG 397
Why stopped
Strategic decisions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-12